Aduro Biotech (ADRO) has an average broker rating of 1.6, which is interpreted as a Buy, as rated by 5 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 considers that the stock is a Sell.
Aduro Biotech (ADRO) stock is expected to deviate a maximum of $5.62 from the average target price of $17.25 for the short term period. 4 Street Experts have initiated coverage on the stock with the most promising target being $22 and the most muted being $11.
For the current week, the company shares have a recommendation consensus of Buy.
Aduro Biotech (NASDAQ:ADRO): stock was range-bound between the intraday low of $14.745 and the intraday high of $15.83 after having opened at $15.56 on Wednesdays session. The stock finally closed in the red at $15.56, a loss of -3.29%. The stock remained in the red for the whole trading day. The total traded volume was 993,081 shares. The stock failed to cross $15.83 in Wednesdays trading. The stocks closing price on Thursday was $15.48.
Aduro BioTech Inc is a United States-based clinical-stage immunotherapy company. The Company has developed or acquired technology platforms designed to activate potent and lasting immune responses against cancer: live, attenuated Listeria, GVAX and cyclic dinucleotides (CDNs). Aduros lead program is an immunotherapy regimen combining Listeria-based CRS-207 and GVAX Pancreas in patients with metastatic pancreatic cancer who have failed at least one therapy. Its pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX. CRS-207 is based on Aduros Listeria platform. ADU-623 is Aduros first clinical bivalent Listeria-based immunotherapy. ADU-214 is a bivalent Listeria-based immunotherapy that targets both mesothelin and an EGFR mutation. CDNs are small molecules that signal through STING and induce a potent immune response. STINGVAX is the combination of CDNs and GVAX.